Biotechnology · Nasdaq

INCYIncyte Corp

Last close
$120.97 -0.6%
52-week range
$89.25 to $132.60
Market cap
$24.7B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$5.14B
+21% vs FY24
Net income
$1.29B
+3,845% vs FY24
Free cash flow
n/a
No prior year to compare
Net cash
$3.10B
Cash $3.10B, no debt reported

Stock price

+20% since Dec 2016

Valuation vs its own 10 years

Below its 10-year median on 1 of 3 multiples

Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.

P/E, trailing
64.2x
13.3x477x
72nd percentile, above its median of 38.3x
Positive-earnings quarters only
Price / sales
4.1x
2.7x21.3x
32nd percentile, below its median of 5.6x
EV / EBITDA
29.5x
9.1x90,397x
55th percentile, above its median of 23.6x
Price / free cash flow
n/a
n/a: Not meaningful (negative or missing)
Median 30.9x, range 20.3x to 529x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
64.2x
Earnings yield
1.6%
Price / sales
4.1x
Price / book
4.4x
Price / operating cash flow
33.1x
EV / EBITDA
29.5x
EV / sales
3.6x
Free cash flow yield
n/aNot reported

Profitability

Gross margin
92.7%
Operating margin
10.4%
Net margin
6.7%
Return on equity
7.1%
Return on capital
5.6%

Growth per year

Revenue, 3 years
+14.8%
Revenue, 5 years
+14.0%
Revenue, 9 years
+18.6%
EPS, 3 years
+61.6%

Balance sheet

Cash and investments
$3.28B
Total debt
n/a
Net cash
$3.28B
Debt / equity
n/a
Current ratio
3.84x

n/a: No debt reported

Shares and dividend

Shares outstanding
204M
Share count, 5 years
-8.0%
Beta, 1 year
0.47
Dividend yield
n/a
Dividend per share, TTM
n/a
Payout ratio
n/a

n/a: No dividend

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $1.56B
RevenueNet income
Gross profitLatest quarter $1.45B
EBITDALatest quarter -$684M
Margins93 / -45 / -50%
GrossOperatingNet
Earnings per shareLatest quarter -$3.86
Cash flowLatest quarter -$675M
OperatingCapexFree
Cash vs debtLatest quarter $3.28B
Cash and investmentsTotal debt
P/E historyNow 64.2x
P/E, median 38.3x dashed
P/S historyNow 4.1x
P/S, median 5.6x dashed

Where the revenue comes from

JAKAFI went from 71% to 60% of revenue in 3 years

Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.

JAKAFIOPZELURAJAKAVI Royalty RevenuesNIKTIMVOMilestone and Contract RevenuesOlumiant RoyaltyOther
FY22
71%10%
$3.39B
FY23
70%9%10%
$3.70B
FY24
66%12%10%
$4.24B
FY25
60%13%9%8%
$5.14B
Fiscal 2025 by product line
Product lineRevenueSharevs FY24
JAKAFI$3.09B60.2%+11%
OPZELURA$678M13.2%+33%
JAKAVI Royalty Revenues$458M8.9%+9%
NIKTIMVO$152M2.9%n/a
Milestone and Contract Revenues$150M2.9%+249%
Olumiant Royalty$145M2.8%+7%
Other$432M8.4%+36%

Biotechnology peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
ONC BeOne Medicines Ltd. $619B +33% 17.8%689x93.6x Not enough history
ABBV AbbVie Inc. $521B +11% 32.2%50.8x7.9x 72nd percentile
AMGN Amgen Inc $252B +8% 32.4%27.0x6.5x 78th percentile
GILD Gilead Sciences, Inc. $208B +7% -7.6%No earnings6.7x No earnings
VRTX Vertex Pharmaceuticals Inc / Ma $137B +10% 33.2%34.7x10.5x 71st percentile
INCY Incyte Corp $24.7B +25% 10.4%64.2x4.1x 72nd percentile

The company

Sector
Health Care
Industry
Biotechnology
Founded
2001
Headquarters
Wilmington, DE
Fiscal year ends
December
Website
incyte.com

What it does

Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about INCY.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 573 active funds. Crowd level: quiet.

Open the Smart money tab